Assessing immunologic risk factors in transplantation

References

• Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346(8), 580–590 (2002).
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Nochy D, Hill GS et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am. J. Transplant. 7(4), 832–841 (2007).
   PubMed Web of Science ®Google Scholar
• Capdevila Plaza L, Cubero JJ, Luna E, Hernandez Gallego R. Progression factors in chronic kidney disease. Immunological mechanisms. Nefrologia 29(Suppl. 1), 7–15 (2009).
   Google Scholar
• Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F. ‘Hyperacute’ renal-homograft rejection in man. N. Engl. J. Med. 279(12), 611–618 (1968).
   PubMed Web of Science ®Google Scholar
• Patel R, Terasaki P. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 280(14), 735–739 (1969).
   PubMed Web of Science ®Google Scholar
• Chapman JR, Taylor CJ, Ting A, Morris PJ. The positive cross-match: antibody class and specificity correlate with graft outcome. Transplant Proc. (1 Pt 1), 725–726 (1987).
   Google Scholar
• Karuppan SS, Lindholm A, Moller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 53(3), 666–673 (1992).
   PubMed Web of Science ®Google Scholar
• Möller E, Söderberg-Nauclér C, Sumitran-Karuppan S. Role of alloimmunity in clinical transplantation. Rev. Immunogenet. 1(3), 309–322 (1999).
   Google Scholar
• Tait BD, Susal C, Gebel HM, Nickerson PW et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95(1), 19–47 (2013).
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365(4), 318–326 (2011).
   PubMed Web of Science ®Google Scholar
• Cook DJ, Fettouh HI, Gjertson DW, Cecka JM. Flow cytometry crossmatching (FCXM) in the UNOS kidney transplant registry. Clin. Transpl. 5, 413–419 (1998).
   Google Scholar
• Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 82(11), 1524–1528 (2006).
   Google Scholar
• Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum. Immunol. 70(8), 574–579 (2009).
   PubMedGoogle Scholar
• Gloor JM, Winters JL, Cornell LD et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am. J. Transplant. 10(3), 582–589 (2010).
   PubMed Web of Science ®Google Scholar
• Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am. J. Transplant. 6(8), 1841–1847 (2006).
   PubMedGoogle Scholar
• Aubert V, Venetz JP, Pantaleo G, Pascual M. Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant? Transplantation 87(12), 1897–1898 (2009).
   Google Scholar
• Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum. Immunol. 70(8), 580–583 (2009).
   PubMedGoogle Scholar
• Billen EV, Christiaans MH, van den Berg-Loonen EM. Clinical relevance of luminex donor-specific crossmatches: data from 165 renal transplants. Tissue Antigens 74(3), 205–212 (2009).
   Google Scholar
• Riethmüller S, Ferrari-Lacraz S, Müller MK et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 90(2), 160–167 (2010).
   PubMed Web of Science ®Google Scholar
• Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol. Dial. Transplant. 27(3), 1231–1238 (2012).
   PubMed Web of Science ®Google Scholar
• Lawrence C, Willicombe M, Brookes PA et al. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 95(2), 341–346 (2013).
   Google Scholar
• Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am. J. Transplant. 9(11), 2561–2570 (2009).
   PubMed Web of Science ®Google Scholar
• Hönger G, Wahrmann M, Amico P, Hopfer H, Böhmig GA, Schaub S. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 89(12), 1471–1475 (2010).
   Google Scholar
• Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91(3), 342–347 (2011).
   PubMed Web of Science ®Google Scholar
• Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum. Immunol. 72(10), 849–858 (2011).
   PubMed Web of Science ®Google Scholar
• Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr. Transplant. 16(1), 12–17 (2012).
   PubMed Web of Science ®Google Scholar
• Freitas MC, Rebellato LM, Ozawa M et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013).
   Google Scholar
• Reinsmoen NL, Lai CH, Heidecke H et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 90(12), 1473–1477 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 92(1), 54–60 (2011).
   PubMed Web of Science ®Google Scholar
• Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352(6), 558–569 (2005).
   PubMed Web of Science ®Google Scholar
• Mi H, Carter V, Gupta A et al. Anti-vimentin antibody detection in recipients of heart-beating and non-heart beating donor kidneys. Transplant. Proc. 37(8), 3269–3271 (2005).
   Google Scholar
• Stastny P. Endothelial monocyte antigens in man. Transplant. Proc. 10(4), 875–877 (1978).
   Google Scholar
• Breimer ME, Rydberg L, Jackson AM et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 87(4), 549–556 (2009).
   PubMed Web of Science ®Google Scholar
• Elgueta R, de Vries VC, Noelle RJ. The immortality of humoral immunity. Immunol. Rev. 236, 139–150 (2010).
   Google Scholar
• Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS. HLA-specific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 83(7), 982–988 (2007).
   Google Scholar
• Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv. Chronic. Kidney Dis. 18(6), 428–432 (2011).
   PubMed Web of Science ®Google Scholar
• Coppolino G, Lucisano G, Bolignano D, Buemi M. Acute cardiovascular complications of hemodialysis. Minerva. Urol. Nefrol. 62(1), 67–80 (2010).
   Google Scholar
• Locke JE, Zachary AA, Warren DS et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am. J. Transplant. 9(9), 2136–2139 (2009).
   PubMedGoogle Scholar
• Ritchey EE, Wallin JD, Shah SV. Chemiluminescence and superoxide anion production by leukocytes from chronic hemodialysis patients. Kidney Int. 19(2), 349–358 (1981).
   PubMed Web of Science ®Google Scholar
• Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am. J. Med. Sci. doi:10.1097/MAJ.0b013e31827f4ee3 (2013) (Epub ahead of print).
   Google Scholar
• Hutchinson IV, Turner DM, Sankaran D, Awad MR, Sinnott PJ. Influence of cytokine genotypes on allograft rejection. Transplant. Proc. 30(3), 862–863 (1998).
   PubMed Web of Science ®Google Scholar
• Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-β1 gene: association with transforming growth factor-β1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66(8), 1014–1020 (1998).
   PubMed Web of Science ®Google Scholar
• Warle MC, Farhan A, Metselaar HJ et al. In vitro cytokine production of TNFα and IL-13 correlates with acute liver transplant rejection. Hum. Immunol. 62(11), 1258–1265 (2001).
   Google Scholar
• Morgun A, Shulzhenko N, Rampim GF et al. Interleukin-2 gene polymorphism is associated with renal but not cardiac transplant outcome. Transplant. Proc. 35(4), 1344–1345 (2003).
   Google Scholar
• Lipkowitz MS, Freedman BI, Langefeld CD et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 83(1), 114–120 (2013).
   Google Scholar
• Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329(5993), 841–845 (2010).
   PubMed Web of Science ®Google Scholar
• Pondrom S. The AJT report: news and issues that affect organ and tissue transplantation. Genetic factor may limit kidney donation. Am. J. Transplant. 12(11), 2865–2866 (2012).
   Google Scholar
• Hutchings A, Purcell WM, Benfield MR. Peripheral blood antigen-presenting cells from African–Americans exhibit increased CD80 and CD86 expression. Clin. Exp. Immunol. 118(2), 247–252 (1999).
   Google Scholar
• Hutchings A, Purcell WM, Benfield MR. Increased costimulatory responses in African-American kidney allograft recipients. Transplantation 71(5), 692–695 (2001).
   Google Scholar
• Wiebe C, Gibson IW, Blydt-Hansen TD et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 12(5), 1157–1167 (2012).
   PubMed Web of Science ®Google Scholar
• LaRosa C, Baluarte HJ, Meyers KE. Outcomes in pediatric solid-organ transplantation. Pediatr. Transplant. 15(2), 128–141 (2011).
   Google Scholar
• Berger JC, Muzaale AD, James N et al. Living kidney donors ages 70 and older: recipient and donor outcomes. Clin. J. Am. Soc. Nephrol. 6(12), 2887–2893 (2011).
   PubMed Web of Science ®Google Scholar
• Matas AJ, Smith JM, Skeans MA et al. OPTN/SRTR 2011 annual data report: kidney. Am. J. Transplant. 13(Suppl. 1), 11–46 (2013).
   PubMed Web of Science ®Google Scholar
• Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 63(7), 968–974 (1997).
   PubMed Web of Science ®Google Scholar
• Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am. J. Transplant. 6(4), 652–658 (2006).
   PubMedGoogle Scholar
• Kaminska D, Tyran B, Mazanowska O et al. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation 84(9), 1118–1124 (2007).
   Google Scholar
• Floerchinger B, Yuan X, Jurisch A et al. Inflammatory immune responses in a reproducible mouse brain death model. Transplant. Immunol. 27(1), 25–29 (2012).
   Google Scholar
• Atkinson C, Floerchinger B, Qiao F et al. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation 127(12), 1290–1299 (2013).
   Google Scholar
• Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat. Rec. 232(2), 194–201 (1992).
   PubMedGoogle Scholar
• Mueller TF, Solez K, Mas V. Assessment of kidney organ quality and prediction of outcome at time of transplantation. Semin. Immunopathol. 33(2), 185–199 (2011).
   Google Scholar
• de Fijter JW, Mallat MJ, Doxiadis II et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J. Am. Soc. Nephrol. 12(7), 1538–1546 (2001).
   Google Scholar
• Choi JY, Kwon OJ, Kang CM. The effect of donor-recipient relationship on long-term outcomes of living related donor renal transplantation. Transplant. Proc. 44(1), 257–260 (2012).
   PubMed Web of Science ®Google Scholar
• Burlingham WJ, Grailer AP, Heisey DM et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N. Engl. J. Med. 339(23), 1657–1664 (1998).
   PubMed Web of Science ®Google Scholar
• van den Boogaardt DE, van Rood JJ, Roelen DL, Claas FH. The influence of inherited and noninherited parental antigens on outcome after transplantation. Transpl. Int. 19(5), 360–371 (2006).
   Web of Science ®Google Scholar
• Dutta P, Dart M, Roenneburg DA, Torrealba JR, Burlingham WJ. Pretransplant immune-regulation predicts allograft tolerance. Am. J. Transplant. 11(6), 1296–1301 (2011).
   PubMed Web of Science ®Google Scholar
• Gjertson DW, Terasaki PI, Takemoto S, Mickey MR. National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. N. Engl. J. Med. 324(15), 1032–1036 (1991).
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 84(2), 137–143 (2007).
   PubMed Web of Science ®Google Scholar
• Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N. Engl. J. Med. 343(15), 1078–1084 (2000).
   PubMed Web of Science ®Google Scholar
• Egfjord M, Jakobsen BK, Ladefoged J. No impact of cross-reactive group human leucocyte antigen class I matching on long-term kidney graft survival. Scand. J. Immunol. 57(4), 362–365 (2003).
   Google Scholar
• Sijpkens YW, Doxiadis II, De Fijter JW et al. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int. 56(5), 1920–1927 (1999).
   Google Scholar
• Lazda VA. Sensitization to HLA by allografts is minimized by matching for HLA-A,B crossreactive groups. Transplant. Proc. 33(1–2), 393–394 (2001).
   Google Scholar
• Crowe DO. The effect of cross-reactive epitope group matching on allocation and sensitization. Clin. Transplant. 17(Suppl. 9), 13–16 (2003).
   Google Scholar
• Everly MJ, Rebellato LM, Haisch CE et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95(3), 410–417 (2013).
   PubMed Web of Science ®Google Scholar
• Willicombe M, Brookes P, Sergeant R et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 94(2), 172–177 (2012).
   PubMed Web of Science ®Google Scholar
• Sellares J, Reeve J, Loupy A et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am. J. Transplant. 13(4), 971–983 (2013).
   PubMed Web of Science ®Google Scholar
• Cecka JM. Outcome statistics of renal transplants with an emphasis on long-term survival. Clin. Transplant. 8(3 Pt 2), 324–327 (1994).
   PubMed Web of Science ®Google Scholar
• Bachelet T, Couzi L, Guidicelli G et al. Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection. Am. J. Transplant. 11(7), 1543–1544 (2011).
   PubMed Web of Science ®Google Scholar
• Jolly EC, Key T, Rasheed H et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am. J. Transplant. 12(10), 2845–2848 (2012).
   Google Scholar
• Vanderlugt CJ, Miller SD. Epitope spreading. Curr. Opin. Immunol. 8(6), 831–836 (1996).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum. Immunol. 66(4), 364–370 (2005).
   PubMed Web of Science ®Google Scholar